Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Receivables (2016 - 2025)

China Pharma Holdings' Receivables history spans 16 years, with the latest figure at $290673.0 for Q4 2025.

  • For Q4 2025, Receivables fell 97.9% year-over-year to $290673.0; the TTM value through Dec 2025 reached $290673.0, down 97.9%, while the annual FY2025 figure was $290673.0, 97.9% down from the prior year.
  • Receivables reached $290673.0 in Q4 2025 per CPHI's latest filing, down from $355789.0 in the prior quarter.
  • In the past five years, Receivables ranged from a high of $14.4 million in Q4 2023 to a low of $91753.0 in Q2 2023.
  • Average Receivables over 5 years is $4.2 million, with a median of $1.3 million recorded in 2021.
  • Peak YoY movement for Receivables: soared 15147.01% in 2024, then plummeted 97.9% in 2025.
  • A 5-year view of Receivables shows it stood at $2.1 million in 2021, then crashed by 78.94% to $450670.0 in 2022, then soared by 3106.0% to $14.4 million in 2023, then dropped by 4.14% to $13.8 million in 2024, then tumbled by 97.9% to $290673.0 in 2025.
  • Per Business Quant, the three most recent readings for CPHI's Receivables are $290673.0 (Q4 2025), $355789.0 (Q3 2025), and $317154.0 (Q2 2025).